SCHEMBL1031969

SCHEMBL1031969

O=Cc1ccc(O)c(OCc2ccccc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
SIRT1 Q96EB6 1/20 0.58
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56
TRIM24 O15164 1/20 0.54
HPGD P15428 1/20 0.54
ALDH5A1 P51649 1/20 0.54
ABAT P80404 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
TRIM33 Q9UPN9 1/20 0.54
CA12 O43570 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
GSK3B P49841 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29927015 1.00 ALDH1A1 (0.62) ALDH1A1SIRT1MAOAMAOBTRIM24
SCHEMBL1180820 0.88 MAOA (0.56) ALDH1A1SIRT1MAOAMAOBSMN1; SMN2
SCHEMBL3923850 0.86 ALDH1A1 (0.54) ALDH1A1SIRT1MAOAMAOBTRIM24
SCHEMBL584489 0.85 TACR2 (0.62) ALDH1A1MAOAMAOBHPGDSMN1; SMN2
SCHEMBL29446267 0.85 TACR2 (0.62) ALDH1A1MAOAMAOBHPGDSMN1; SMN2
Ethyl Vanillin SCHEMBL28162512 0.85 ALDH1A1 (0.72) ALDH1A1SIRT1TRIM24HPGDALDH5A1
SCHEMBL2557728 0.85 TACR2 (0.67) ALDH1A1SIRT1MAOAMAOBTRIM24
SCHEMBL9811349 0.84 MAOA (0.52) ALDH1A1SIRT1MAOAMAOBSMN1; SMN2
SCHEMBL6452430 0.83 KDR (0.48) ALDH1A1SIRT1MAOAMAOBCA12
SCHEMBL14686072 0.82 KDM4E (0.70) ALDH1A1HPGDTDP1CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103539642-A Method for preparing 3,4,5-trimethoxy-3'-hydroxy-4'-alkoxy diphenylethane SHANGHAI INST TECHNOLOGY 2014-01-29 CN claimed
EP-3828163-B1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME AUTOTAC INC (KR) 2026-05-20 EP disclosed
EP-4633738-A1 CYTOTOXIC COMPOUNDS Pheon Therapeutics Ltd (GB) 2025-10-22 EP disclosed
US-12427346-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same AUTOTAC INC. (KR) 2025-09-30 US disclosed
CN-120698867-A Preparation method of 4-ethoxy-3-hydroxybenzaldehyde 枣阳市福星化工有限公司 2025-09-26 CN disclosed
CN-118878502-B 4H-benzo [ B ] pyran derivative B86, preparation method and application thereof in resisting ricefield eel rhabdovirus 中国水产科学研究院长江水产研究所 2025-04-29 CN disclosed
EP-4458916-A1 PHOTOCATALYTICALLY ACTIVE COATING COMPOSITION, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF TriOptoTec GmbH (DE) 2024-11-06 EP disclosed
CN-118878502-A 4H-benzo [ B ] pyran derivative B86, preparation method and application thereof in resisting ricefield eel rhabdovirus 中国水产科学研究院长江水产研究所 2024-11-01 CN disclosed
US-12024521-B2 Isoquinoline derivatives, methods of synthesis and uses thereof PROSETTA BIOSCIENCES, INC. (US) 2024-07-02 US disclosed
CN-111494395-B Carbidopa and levodopa prodrugs and their use for treating parkinson's disease 艾伯维公司 2024-06-21 CN disclosed
WO-2002022612-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-21 WO disclosed
WO-2002017915-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-07 WO disclosed
WO-2002004412-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2002-01-17 WO disclosed
EP-1121338-A1 METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS Millennium Pharmaceuticals, Inc. (US) 2001-08-08 EP disclosed
US-6140353-A USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 2000-10-31 US disclosed
WO-2000023409-A1 METHOD FOR SYNTHESIZING DIARYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS, INCLUDING TETRAHYDROFURANS LEUKOSITE, INC. (US) 2000-04-27 WO disclosed
EP-0921116-A1 N-(4-carbamimido-phenyl)-glycine amide derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-06-09 EP disclosed
EP-0167204-B1 METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1989-09-27 EP disclosed
US-4673671-A CONVERSION TO MONO O-PHOSPHATE ESTER SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) 1987-06-16 US disclosed
EP-0167204-A1 Method for improving the absorption and effectiveness of a catecholamine compound SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1986-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024521-B2 Isoquinoline derivatives, methods of synthesis and uses thereof POLRMT, MAVS, SYNCRIP ALDH1A1 3238/4885SIRT1 1120/4885MAOA 1165/4885
US-12427346-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same SQSTM1, ATG7, BECN1 ALDH1A1 4677/4885SIRT1 276/4885MAOA 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.